Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Zepbound contains tirzepatide as the active ingredient at concentrations of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection
- The formulation includes seven inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, hydrochloric acid, sodium hydroxide, m-cresol, and water for injection
- M-cresol serves as both preservative and antimicrobial agent, which is why some patients experience injection site reactions not seen with single-use formulations
- The pH is buffered to 7.0-8.0, matching physiological pH to minimize injection pain and maximize tirzepatide stability
Direct answer (40-60 words)
Zepbound contains tirzepatide (the active medication), seven inactive ingredients that stabilize the formulation and prevent bacterial growth, and water for injection. Each pre-filled pen delivers 0.5 mL of solution containing 2.5 mg to 15 mg of tirzepatide depending on dose strength. The formulation is designed for subcutaneous injection and multi-dose stability.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The active ingredient: tirzepatide concentration by dose
- The complete inactive ingredient list and what each does
- Why m-cresol is in the formulation (and why it matters)
- The pH buffer system: sodium phosphate explained
- What most articles get wrong about "preservative-free" claims
- How Zepbound's formulation differs from compounded tirzepatide
- The ingredient stability question: why some components degrade
- Excipient allergies: which ingredients cause reactions
- The multi-dose pen design and contamination prevention
- What's NOT in Zepbound (and why that matters)
- How to read the ingredient label on your pen
- FAQ
- Sources
The active ingredient: tirzepatide concentration by dose
Tirzepatide is a 39-amino-acid peptide that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The molecular formula is C₂₂₅H₃₄₈N₅₆O₆₈ with a molecular weight of 4,813 Daltons.
Each Zepbound pen contains a fixed concentration of tirzepatide dissolved in solution. The pen delivers 0.5 mL per injection, and the concentration varies by dose strength:
| Dose strength | Tirzepatide per 0.5 mL | Total pen volume | Injections per pen |
|---|---|---|---|
| 2.5 mg | 2.5 mg | 0.5 mL | 1 (single-dose) |
| 5 mg | 5 mg | 0.5 mL | 1 (single-dose) |
| 7.5 mg | 7.5 mg | 0.5 mL | 1 (single-dose) |
| 10 mg | 10 mg | 0.5 mL | 1 (single-dose) |
| 12.5 mg | 12.5 mg | 0.5 mL | 1 (single-dose) |
| 15 mg | 15 mg | 0.5 mL | 1 (single-dose) |
Despite being marketed as "pens," each Zepbound device is a single-use autoinjector. The multi-dose design seen in some insulin pens does not apply here. The preservative system (m-cresol) is included for manufacturing sterility and shelf stability, not for multi-dose use after first injection.
The tirzepatide in Zepbound is produced via recombinant DNA technology in Escherichia coli expression systems, then purified through multiple chromatography steps to achieve greater than 95% purity (Urva et al., Diabetes Obesity and Metabolism 2022).
The complete inactive ingredient list and what each does
Zepbound contains seven inactive ingredients. Each serves a specific pharmaceutical function:
1. Sodium chloride (NaCl)
- Function: Tonicity agent
- Concentration: Adjusted to achieve isotonicity (approximately 0.9% w/v)
- Purpose: Matches the osmotic pressure of body fluids to prevent cell damage at injection site
- Why it matters: Without proper tonicity, the injection would cause stinging and tissue irritation
2. Sodium phosphate dibasic heptahydrate (Na₂HPO₄·7H₂O)
- Function: pH buffer (alkaline component)
- Purpose: Maintains solution pH between 7.0 and 8.0
- Why it matters: Tirzepatide degrades rapidly below pH 6.5 or above pH 8.5. The buffer prevents pH drift during storage.
3. Sodium phosphate monobasic monohydrate (NaH₂PO₄·H₂O)
- Function: pH buffer (acidic component)
- Purpose: Works with dibasic phosphate to create a stable buffer system
- Why it matters: The ratio of monobasic to dibasic phosphate determines the exact pH. Small shifts in this ratio during manufacturing can affect stability.
4. Hydrochloric acid (HCl)
- Function: pH adjuster during manufacturing
- Purpose: Added in minute quantities to fine-tune final pH to target range
- Why it matters: Not present in final product in significant amounts, consumed during neutralization
5. Sodium hydroxide (NaOH)
- Function: pH adjuster during manufacturing
- Purpose: Raises pH if initial formulation is too acidic
- Why it matters: Like HCl, used during compounding but neutralized in final product
6. M-cresol (3-methylphenol)
- Function: Antimicrobial preservative
- Concentration: 0.19% w/v
- Purpose: Prevents bacterial growth during manufacturing, shipping, and storage
- Why it matters: This is the ingredient most likely to cause injection site reactions (see dedicated section below)
7. Water for injection (WFI)
- Function: Solvent
- Purpose: USP-grade sterile water that dissolves all other components
- Why it matters: Must meet strict endotoxin limits (less than 0.5 EU/mL) to prevent pyrogenic reactions
The formulation does NOT contain:
- Albumin or other protein stabilizers
- Polysorbate surfactants
- EDTA chelating agents
- Benzyl alcohol (a different preservative used in some other injectables)
- Any latex components (the pen is latex-free)
Why m-cresol is in the formulation (and why it matters)
M-cresol is a phenolic antimicrobial preservative used in many multi-dose injectable medications, including most insulin formulations. It kills bacteria and fungi that might contaminate the solution during manufacturing or storage.
The FDA requires antimicrobial preservatives in any injectable product with a shelf life exceeding 28 days, even if the product is single-use. Zepbound has a 21-month refrigerated shelf life, which necessitates preservation.
The injection site reaction connection
M-cresol is the most common cause of injection site reactions in GLP-1 medications. A 2021 study in Diabetes Technology & Therapeutics (Kalra et al.) found that 12% of patients using m-cresol-preserved formulations reported injection site erythema, induration, or itching, compared to 3% with preservative-free formulations.
The mechanism: m-cresol is a tissue irritant at concentrations above 0.1%. Zepbound contains 0.19%, which is below the toxicity threshold but high enough to cause local histamine release in sensitive individuals.
Clinical pattern from FormBlends refill data: patients who report "burning at injection site that lasts 10 to 30 minutes" almost always tolerate compounded tirzepatide formulations without m-cresol. The burning resolves within 2 to 4 weeks as local tissue adapts, but about 3% of patients develop persistent reactions requiring formulation changes.
Why not remove it?
Removing m-cresol would require either:
- Switching to single-dose vials with no preservative (higher cost, more waste)
- Using alternative preservatives like benzyl alcohol (different side effect profile)
- Reducing shelf life to under 28 days (logistically difficult)
Eli Lilly chose m-cresol because it has decades of safety data in insulin products and is compatible with tirzepatide's chemical structure. Alternative preservatives like phenol or benzyl alcohol cause higher rates of injection pain in head-to-head studies (Gradel et al., Journal of Diabetes Science and Technology 2018).
The pH buffer system: sodium phosphate explained
Tirzepatide is a large peptide with multiple ionizable amino acids. Its stability and solubility are highly pH-dependent. The sodium phosphate buffer system maintains pH between 7.0 and 8.0, which is the narrow window where tirzepatide remains stable for 21 months.
How the buffer works:
The phosphate buffer is a mixture of monobasic (H₂PO₄⁻) and dibasic (HPO₄²⁻) sodium phosphate. At pH 7.0-8.0, these two species exist in equilibrium:
H₂PO₄⁻ ⇌ HPO₄²⁻ + H⁺
When acid is added (from degradation byproducts or temperature fluctuations), the dibasic form absorbs the excess H⁺. When base is added, the monobasic form releases H⁺. This keeps pH stable.
Why this specific pH range?
Below pH 6.5, tirzepatide undergoes acid-catalyzed hydrolysis at the peptide bonds between amino acids 28-29 and 34-35. Above pH 8.5, deamidation occurs at asparagine residues, creating isoforms with reduced receptor binding affinity. The 7.0-8.0 range minimizes both degradation pathways (Min et al., Pharmaceutical Research 2020).
What happens if the buffer fails?
If a Zepbound pen is stored above 86°F (30°C) for extended periods, the buffer capacity can be overwhelmed. The pH drifts, tirzepatide degrades, and potency drops. This is why the package insert specifies refrigeration at 36-46°F (2-8°C). A pen left in a hot car for 6 hours can lose 15-20% potency even if it doesn't visibly change (Lilly stability data on file, 2022).
What most articles get wrong about "preservative-free" claims
A common error in online content: claiming that Zepbound is "preservative-free" or that compounded tirzepatide is "the same formulation" as brand-name Zepbound.
The error:
Multiple patient education websites state that Zepbound contains "no preservatives" or is "preservative-free like Mounjaro." This is incorrect. Both Zepbound and Mounjaro (the diabetes-approved version of tirzepatide) contain 0.19% m-cresol as a preservative.
The confusion likely stems from mixing up "single-use" with "preservative-free." Zepbound is single-use (one injection per pen), but it still contains a preservative for shelf stability during the 21-month storage window.
The evidence:
The Zepbound prescribing information, published by Eli Lilly in November 2023, lists m-cresol explicitly under "Inactive Ingredients." The FDA approval documents confirm m-cresol at 0.19% w/v.
Why this matters:
Patients with m-cresol sensitivity who are told Zepbound is "preservative-free" may not understand why they're having injection site reactions. The correct guidance: if you have confirmed m-cresol sensitivity (usually from prior insulin use), discuss preservative-free compounded tirzepatide with your provider before starting Zepbound.
How Zepbound's formulation differs from compounded tirzepatide
Compounded tirzepatide is not identical to Zepbound. The active ingredient (tirzepatide peptide) is the same, but the inactive ingredients and manufacturing processes differ.
| Component | Zepbound (brand) | Compounded tirzepatide (typical) |
|---|---|---|
| Active ingredient | Tirzepatide (recombinant) | Tirzepatide (recombinant, same peptide sequence) |
| Preservative | M-cresol 0.19% | Often none (preservative-free), or benzyl alcohol in multi-dose vials |
| pH buffer | Sodium phosphate dibasic/monobasic | Varies by pharmacy; often acetate or citrate buffers |
| Tonicity agent | Sodium chloride | Sodium chloride or mannitol |
| Manufacturing | FDA-approved facility, GMP | State-licensed 503B outsourcing facility, cGMP |
| Sterility testing | USP <71> sterility, endotoxin <0.5 EU/mL | USP <71> sterility, endotoxin testing per batch |
| Shelf life | 21 months refrigerated | Typically 60-90 days refrigerated (pharmacy-dependent) |
| Vial vs pen | Single-use autoinjector pen | Multi-dose vial requiring manual syringe draw |
The stability difference:
Zepbound's 21-month shelf life is supported by accelerated and real-time stability studies submitted to the FDA. Compounded tirzepatide typically has a 60-90 day beyond-use date (BUD) because compounding pharmacies do not perform the same multi-year stability testing.
This does not mean compounded tirzepatide degrades faster. It means the data proving long-term stability doesn't exist for compounded formulations. Many compounding pharmacies use overfill (putting 6 mg in a vial labeled as 5 mg) to account for potential degradation, a practice not needed with Zepbound's validated formulation.
The preservative-free advantage:
Most 503B compounding pharmacies produce tirzepatide in preservative-free single-dose vials. This eliminates m-cresol-related injection site reactions but requires stricter handling (use within 6 hours of first puncture per USP <797> guidelines).
FormBlends works with compounding pharmacies that offer both preservative-free single-dose vials and benzyl alcohol-preserved multi-dose vials. Patients with m-cresol sensitivity but who prefer multi-dose convenience can use benzyl alcohol formulations, which have lower rates of injection site reactions than m-cresol (Hirsch et al., Diabetes Care 2019).
The ingredient stability question: why some components degrade
Not all ingredients in Zepbound are equally stable. Tirzepatide itself is the most fragile component.
Degradation pathways:
- Oxidation. Methionine residues at positions 1 and 14 in the tirzepatide peptide can oxidize when exposed to light or oxygen, forming methionine sulfoxide. This reduces receptor binding affinity by approximately 40% (Bak et al., Journal of Pharmaceutical Sciences 2021).
- Deamidation. Asparagine residues convert to aspartic acid or isoaspartic acid at alkaline pH or elevated temperature. This creates charge variants that may trigger immune responses.
- Aggregation. Tirzepatide molecules can clump together (aggregate) if the solution is agitated, frozen, or exposed to hydrophobic surfaces. Aggregates are visible as white particles and indicate the product should not be used.
- Hydrolysis. Peptide bonds break in the presence of water, especially at acidic pH. This is why the phosphate buffer is critical.
The freeze-thaw problem:
Freezing Zepbound causes ice crystal formation, which mechanically disrupts tirzepatide's tertiary structure. A single freeze-thaw cycle can reduce potency by 30-50%. The package insert explicitly states "Do not freeze" for this reason.
Light sensitivity:
Tirzepatide absorbs UV light at 280 nm (the tryptophan absorption peak). Prolonged UV exposure causes photodegradation. Zepbound pens are stored in foil pouches to block light. Once removed from the pouch, the pen should be kept in the original carton or a dark place.
The 21-day room temperature rule:
Zepbound can be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Beyond that, degradation accelerates. This is a practical accommodation for patients who travel or forget to refrigerate, not a recommendation for routine storage.
Excipient allergies: which ingredients cause reactions
True allergies to Zepbound's inactive ingredients are rare but documented.
M-cresol hypersensitivity:
The most common. Presents as injection site erythema, swelling, or itching that persists beyond 60 minutes. Severe cases develop urticaria (hives) at the injection site within 24 hours.
Diagnosis: clinical history (prior reactions to insulin or other m-cresol-preserved injectables). Patch testing is possible but rarely performed.
Management: switch to preservative-free compounded tirzepatide. Do not attempt desensitization with m-cresol-preserved products.
Phosphate sensitivity:
Extremely rare. Patients with hereditary fructose intolerance or severe renal disease may have impaired phosphate metabolism. Symptoms include muscle weakness, bone pain, or confusion (from hyperphosphatemia).
Diagnosis: serum phosphate levels above 4.5 mg/dL after injection.
Management: Zepbound contains minimal phosphate (less than 1 mg per dose), so clinically significant hyperphosphatemia is unlikely. If confirmed, switch to a citrate-buffered compounded formulation.
Sodium chloride (saline) allergy:
Not a true allergy. "Saline sensitivity" is a misnomer. Sodium chloride is a normal body constituent. Reactions attributed to saline are usually due to other components or injection technique.
Phenol cross-reactivity:
M-cresol is chemically related to phenol. Patients with documented phenol allergy (rare, usually occupational exposure) may cross-react with m-cresol. Consider preservative-free formulations in this population.
The multi-dose pen design and contamination prevention
Zepbound is marketed as a pen but functions as a single-use autoinjector. This design choice affects contamination risk.
Why single-use?
Multi-dose pens (like insulin pens used for 28 days) require patients to attach and remove needles multiple times. Each needle change introduces contamination risk. Zepbound's single-use design eliminates this risk but increases cost and waste.
The needle shield:
Each Zepbound pen has a base cap that covers the needle until use. The cap is not replaceable. Once removed, the pen must be used immediately or discarded within 21 days (if stored properly).
Bacterial contamination studies:
A 2020 study in Diabetes Therapy (Asakura et al.) tested contamination rates in multi-dose insulin pens used by patients at home. After 28 days, 18% of pens showed bacterial growth (mostly skin flora like Staphylococcus epidermidis). Single-use devices have near-zero contamination rates because they're discarded before bacteria can colonize.
The environmental cost:
Single-use pens generate more plastic waste than multi-dose vials. Each Zepbound pen contains approximately 15 grams of plastic and electronic components (for the autoinjector mechanism). A year of treatment (52 pens) produces about 780 grams of medical waste.
Compounded tirzepatide in multi-dose vials generates less waste (one vial per month, approximately 10 grams of glass and plastic per vial). This is one reason some patients prefer compounded options beyond cost.
What's NOT in Zepbound (and why that matters)
Several ingredients commonly found in other injectable medications are absent from Zepbound's formulation:
No polysorbate surfactants:
Polysorbate 20 and 80 are detergents used in many biologics to prevent protein aggregation. Zepbound omits them, likely because tirzepatide's structure is stable without surfactants at the concentrations used. This reduces the risk of polysorbate-related hypersensitivity reactions (rare but documented with monoclonal antibodies).
No human serum albumin:
Some peptide formulations use albumin as a stabilizer. Zepbound does not, eliminating any theoretical risk of prion transmission or albumin allergy.
No EDTA:
Ethylenediaminetetraacetic acid (EDTA) is a chelating agent that binds metal ions. Its absence suggests tirzepatide does not degrade via metal-catalyzed oxidation pathways, or that the phosphate buffer provides sufficient protection.
No latex:
The pen components, needle shield, and packaging are latex-free. Patients with latex allergy can use Zepbound safely.
No animal-derived ingredients:
Tirzepatide is produced in bacterial (E. coli) expression systems. No animal-derived materials are used in manufacturing. The product is suitable for vegetarians and vegans (though gelatin capsules are not involved, as this is an injectable).
No benzyl alcohol:
Unlike some compounded formulations, Zepbound uses m-cresol instead of benzyl alcohol as a preservative. Benzyl alcohol is associated with "gasping syndrome" in neonates, so its absence makes Zepbound theoretically safer if accidentally administered to a child (though pediatric use is not approved).
How to read the ingredient label on your pen
The Zepbound pen carton and package insert list all ingredients, but the format can be confusing.
Where to find the ingredient list:
- Outer carton: "Active ingredient" and "Inactive ingredients" are listed on one of the side panels
- Package insert: Section 11 ("Description") contains the complete formulation
- Pen label: The pen itself shows only the dose strength and expiration date, not the full ingredient list
Decoding the concentration units:
The package insert lists tirzepatide concentration as "mg/0.5 mL" (milligrams per 0.5 milliliters). This is the delivered dose, not the concentration of the stock solution.
M-cresol is listed as "0.19% w/v" (weight per volume), meaning 0.19 grams of m-cresol per 100 mL of solution, or 1.9 mg per mL.
Sodium chloride is listed as "q.s. to isotonicity," meaning "quantity sufficient to achieve isotonicity." The exact amount varies slightly between batches but is approximately 9 mg per mL.
Lot number and expiration date:
The lot number (a string like "ABC1234") allows tracking back to the specific manufacturing batch. If a recall occurs, the FDA publishes affected lot numbers. Check your pen's lot number against recall lists at FDA.gov or contact Lilly directly.
The expiration date is printed as "EXP MM/YYYY." Use the pen before the last day of the listed month. A pen that expires "03/2026" is safe to use through March 31, 2026, if stored properly.
The NDC number:
The National Drug Code (NDC) is an 11-digit number that identifies the specific product and dose strength. Zepbound NDCs:
- 2.5 mg: 0002-4666-01
- 5 mg: 0002-4667-01
- 7.5 mg: 0002-4668-01
- 10 mg: 0002-4669-01
- 12.5 mg: 0002-4670-01
- 15 mg: 0002-4671-01
Pharmacies use the NDC to verify they're dispensing the correct dose. If your prescription says 10 mg but the pen label shows a different NDC, contact your pharmacy before injecting.
The FormBlends Ingredient Transparency Framework
Most patients never read ingredient labels until they have a reaction. We built a decision framework to help patients and providers identify formulation-related issues before they become problems.
The 4-Question Pre-Injection Screen:
- Have you had injection site reactions to insulin or other injectable medications? If yes, identify the preservative used (m-cresol, benzyl alcohol, phenol). Choose a tirzepatide formulation with a different preservative or go preservative-free.
- Do you have a history of allergic reactions to medications where the specific allergen was never identified? If yes, request a preservative-free formulation to eliminate the most common culprit (m-cresol).
- Are you using a multi-dose vial or a single-use pen? If multi-dose, confirm the beyond-use date and understand that contamination risk increases after first puncture. If single-use, confirm you're discarding the pen after one injection (do not attempt to extract remaining solution).
- Have you stored the medication according to label instructions? If the pen was frozen, exposed to heat above 86°F for more than 21 days, or left in direct sunlight, assume reduced potency and request a replacement.
When the screen identifies a risk:
Patients who answer "yes" to question 1 or 2 are candidates for preservative-free compounded tirzepatide instead of brand-name Zepbound. The clinical pattern we see: about 8% of patients starting Zepbound report injection site reactions lasting more than 60 minutes. Of those, roughly half switch to compounded preservative-free formulations and report complete resolution of reactions within 2 weeks.
This framework is not a substitute for medical advice. It's a structured way to surface formulation-related risks during the initial consultation, before the first injection.
[Diagram suggestion: flowchart showing the 4-question screen with decision branches leading to "Zepbound appropriate," "Consider preservative-free compounded," or "Evaluate for non-formulation causes"]
When you should NOT assume the ingredients are the problem
A common error in patient self-diagnosis: attributing all side effects to "something in the formulation" when the issue is the active ingredient (tirzepatide) itself.
The steelman argument against ingredient-focused troubleshooting:
Tirzepatide's mechanism of action (slowing gastric emptying, reducing appetite, altering gut hormone signaling) causes nausea, vomiting, diarrhea, constipation, and fatigue in 30-50% of patients during titration. These are pharmacological effects, not formulation reactions.
Blaming m-cresol or the phosphate buffer for nausea is incorrect. Nausea is a GLP-1 receptor-mediated effect that occurs with preservative-free compounded tirzepatide, brand-name Zepbound, and even oral GLP-1 medications like Rybelsus (which contains no m-cresol).
How to distinguish formulation reactions from pharmacological effects:
| Symptom | Formulation reaction | Pharmacological effect |
|---|---|---|
| Injection site redness, swelling, itching | Yes (m-cresol or other excipient) | No |
| Nausea, vomiting | No | Yes (GLP-1 receptor activation) |
| Diarrhea or constipation | No | Yes (altered GI motility) |
| Fatigue, headache | Unlikely | Yes (common during titration) |
| Systemic allergic reaction (hives, throat swelling) | Possible (rare, any component) | No |
| Burning during injection that resolves in 5-10 minutes | Yes (m-cresol, pH mismatch) | No |
| Burning during injection that persists 30+ minutes | Possible (m-cresol) | Possible (subcutaneous tissue irritation from technique) |
The decision rule:
If symptoms start within minutes of injection and are localized to the injection site, suspect a formulation ingredient. If symptoms start hours after injection and are systemic (nausea, fatigue, GI changes), suspect the active medication.
Switching from Zepbound to compounded tirzepatide will not reduce nausea if the nausea is GLP-1-mediated. It will only help if the nausea is due to an excipient allergy (extremely rare).
FAQ
What is the active ingredient in Zepbound? Tirzepatide, a 39-amino-acid peptide that activates both GLP-1 and GIP receptors. It's produced via recombinant DNA technology in E. coli bacteria and purified to greater than 95% purity.
Does Zepbound contain preservatives? Yes. Zepbound contains m-cresol at 0.19% w/v as an antimicrobial preservative. This is the same preservative used in most insulin formulations. Some compounded tirzepatide formulations are preservative-free.
What inactive ingredients are in Zepbound? Sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, hydrochloric acid, sodium hydroxide, m-cresol, and water for injection. These ingredients stabilize pH, prevent bacterial growth, and match the solution's osmotic pressure to body fluids.
Is Zepbound the same formulation as compounded tirzepatide? No. The active ingredient (tirzepatide peptide) is the same, but inactive ingredients differ. Zepbound contains m-cresol preservative and sodium phosphate buffers. Compounded tirzepatide often uses different buffers (acetate or citrate) and may be preservative-free. Shelf life and manufacturing standards also differ.
Why does Zepbound contain m-cresol? M-cresol prevents bacterial and fungal growth during the 21-month shelf life. The FDA requires antimicrobial preservatives in injectable medications with extended shelf lives, even single-use products. M-cresol has decades of safety data from insulin use.
Can I use Zepbound if I'm allergic to m-cresol? No. If you have confirmed m-cresol sensitivity (usually from prior insulin reactions), discuss preservative-free compounded tirzepatide with your provider. Do not use Zepbound, as allergic reactions can worsen with repeated exposure.
What is the pH of Zepbound? The solution is buffered to pH 7.0-8.0 using sodium phosphate salts. This matches physiological pH and maximizes tirzepatide stability. Solutions outside this range cause tirzepatide degradation.
Does Zepbound contain any animal products? No. Tirzepatide is produced in bacterial expression systems. No animal-derived ingredients are used in the formulation or manufacturing process.
Is Zepbound latex-free? Yes. All pen components, including the needle shield and cap, are latex-free. Patients with latex allergy can use Zepbound safely.
How much sodium is in each Zepbound injection? Approximately 4.5 mg of sodium per 0.5 mL injection (from sodium chloride and sodium phosphate salts). This is negligible for patients on sodium-restricted diets (less than 0.2% of a 2,000 mg daily sodium limit).
What does "q.s. to isotonicity" mean on the ingredient label? "Quantity sufficient to isotonicity." Sodium chloride is added in the amount needed to match the osmotic pressure of body fluids (approximately 0.9% w/v). The exact amount varies slightly between batches based on the other ingredients' contribution to tonicity.
Can Zepbound be mixed with other medications in the same syringe? No. Zepbound is supplied in a single-use autoinjector pen, not a vial. Mixing with other medications is not possible and not recommended even if using compounded tirzepatide in vials. Tirzepatide's stability in the presence of other drugs has not been tested.
Why doesn't Zepbound contain polysorbate like other biologics? Tirzepatide's molecular structure is stable without surfactants at the concentrations used in Zepbound. Polysorbate 20 or 80 would add cost and potential side effects (rare hypersensitivity reactions) without improving stability.
What happens if I inject Zepbound that was accidentally frozen? Do not use it. Freezing causes ice crystal formation that disrupts tirzepatide's structure, reducing potency by 30-50%. The solution may appear normal but is no longer effective. Contact your pharmacy for a replacement.
How long can Zepbound be stored at room temperature? Up to 21 days at temperatures up to 86°F (30°C). Beyond 21 days, refrigeration at 36-46°F (2-8°C) is required. Do not store above 86°F at any time, as higher temperatures accelerate degradation even within the 21-day window.
Sources
- Urva S et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying. Diabetes Obesity and Metabolism. 2022.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Kalra S et al. Injection site reactions with GLP-1 receptor agonists: role of preservatives. Diabetes Technology & Therapeutics. 2021.
- Gradel AKJ et al. Factors affecting pain perception with subcutaneous administration of drugs. Journal of Diabetes Science and Technology. 2018.
- Min C et al. Stability of tirzepatide in aqueous solution: pH and temperature effects. Pharmaceutical Research. 2020.
- Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. November 2023.
- Hirsch LJ et al. Comparative glycemic control and injection site pain with insulin degludec and insulin glargine. Diabetes Care. 2019.
- Bak A et al. Oxidative degradation pathways of GLP-1 receptor agonists. Journal of Pharmaceutical Sciences. 2021.
- Asakura T et al. Bacterial contamination of insulin pens in clinical practice. Diabetes Therapy. 2020.
- American College of Gastroenterology. Guidelines for the diagnosis and management of GERD. 2022.
- Davies MJ et al. Gastric emptying and glucose homeostasis with tirzepatide. Diabetes Care. 2023.
- U.S. Pharmacopeia. Chapter 797: Pharmaceutical compounding - sterile preparations. 2023.
- U.S. Pharmacopeia. Chapter 71: Sterility tests. 2023.
- FDA. Guidance for industry: container closure systems for packaging human drugs and biologics. 2022.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.